Seizing “magic moment” for machine learning, startup Seismic unveils $101M

Seizing “magic moment” for machine learning, startup Seismic unveils $101M

Source: 
MedCity News
snippet: 

Machine learning is core to the drug research of Seismic Therapeutic, a new biotech startup developing novel drugs for immunology indications. CEO Jo Viney said the company’s initial focus is addressing dysregulation of adaptive immunity.